Posted by Michael Wonder on 26 Aug 2021
Government eases criteria for haemophilia A drug reimbursement
26 August 2021 - The Government said it would ease the immune tolerance induction treatment criteria for haemophilia A drug Hemlibra (emicizumab).
In January, the government expanded the reimbursement scope but added failure of immune tolerance induction treatment as the criteria for reimbursement, which made it more difficult for paediatric patients to receive Hemlibra injections.
